@article{0ef1f9ca63b2433a9ee9ef3307d80c87,
title = "The Mystic Role of Tumor Mutational Burden in Selecting Patients with Lung Cancer for First-Line Immunotherapy",
author = "Waqar, {Saiama N.} and Ramaswamy Govindan",
note = "Funding Information: served on advisory boards for AbbVie, Inivata, Pfizer, Genentech, Bristol-Myers Squibb, Roche, Nektar, Merck, Celgene, Partner Therapeutics, GlaxoSmithKline, Jounce, and Achilles and has served as a consultant for AbbVie, Eli Lilly and Company, AstraZeneca, Pfizer, Genentech, Millennium Pharm, F. Hoffmann-La Roche, NeoHealth, Janssen, Amgen, and GenePlus. Dr Waqar has received support through the UM1 CA186704-01 grant from the National Institutes of Health/National Cancer Institute and has served as institutional principal investigator for studies funded by AstraZeneca, AbbVie, F. Hoffmann-La Roche, Ariad, Pfizer, Hengrui Therapeutics, XCovery, EMD Serono, Eli Lilly and Company, Stemcentrx, Ignyta Inc, Bristol-Myers Squibb, Synermore, Novartis, Merck, Celgene, NewLink Genetics Corp, Genentech, and Checkpoint Therapeutics.",
year = "2020",
month = may,
doi = "10.1001/jamaoncol.2020.0264",
language = "English",
volume = "6",
pages = "674--675",
journal = "JAMA oncology",
issn = "2374-2437",
number = "5",
}